

NOTICE OF AGM – ASX LISTING RULE 3.13.1

Melbourne, Australia, 19 October 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or **the Company**), a medical diagnostics company, advises that the Annual General Meeting is currently scheduled for 26 November 2020. Due to COVID-19 restrictions the meeting will be held online. An item of business at the AGM will be the re-election of directors. The closing date for the receipt of nominations from any person wishing to be considered for election as a director is Monday, 26 October 2020. Nominations must be received at the Company's registered office no later than 5:00pm on this date.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting which will be provided in due course.

Authorised for release by Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS:

Dr Learne Hinch
CEO
E leearne@bard1.com
M +61 400 414 416

Dr Geoff Cumming
Non-Executive Chairman
E geoff.cumming@bard1.com
M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or **Company**) is a leading Australian-based medical diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on the development and commercialisation of best in class lifesaving diagnostic solutions for health care professionals and patients. The cancer diagnostics portfolio includes the marketed hTERT test used as an adjunct to urine cytology testing and diagnostic tests in development for ovarian, breast, lung, prostate and pancreatic cancers. For more information on BARD1, see www.bard1.com.